Perovskite solar cell has gained widespread attention as a promising technology for renewable energy.However, their commercial viability has been hampered by their long-term stability and potential Pb leakage. Herein,...Perovskite solar cell has gained widespread attention as a promising technology for renewable energy.However, their commercial viability has been hampered by their long-term stability and potential Pb leakage. Herein, we demonstrate a bifunctional passivator of the potassium tartrate(PT) to address both challenges. PT minimizes the Pb leakage in perovskites and also heals cationic vacancy defects, resulting in improved device performance and stability. Benefiting from PT modification, the power conversion efficiency(PCE) is improved to 23.26% and the Pb leakage in unencapsulated films is significantly reduced to 9.79 ppm. Furthermore, the corresponding device exhibits no significant decay in PCE after tracking at the maximum power point(MPP) for 2000 h under illumination(LED source, 100 mW cm^(-2)).展开更多
BACKGROUND Helicobacter pylori(H.pylori)infects over half the global population,causing gastrointestinal diseases like dyspepsia,gastritis,duodenitis,peptic ulcers,GMALT lymphoma,and gastric adenocarcinoma.Eradicating...BACKGROUND Helicobacter pylori(H.pylori)infects over half the global population,causing gastrointestinal diseases like dyspepsia,gastritis,duodenitis,peptic ulcers,GMALT lymphoma,and gastric adenocarcinoma.Eradicating H.pylori is crucial for treating and preventing these conditions.While conventional proton pump inhibitor(PPI)-based triple therapy is effective,there’s growing interest in longer acid suppression therapies.Potassium competitive acid blocker(P-CAB)triple and dual therapy are new regimens for H.pylori eradication.Initially used in Asian populations,vonoprazan(VPZ)has been recently Food and Drug Administration-approved for H.pylori eradication.AIM To assess the efficacy of regimens containing P-CABs in eradicating H.pylori infection.METHODS This study,following PRISMA 2020 guidelines,conducted a systematic review and meta-analysis by searching MEDLINE and Scopus libraries for randomized clinical trials(RCTs)or observational studies with the following command:[("Helicobacter pylori"OR"H pylori")AND("Treatment"OR"Therapy"OR"Eradication")AND("Vonaprazan"OR"Potassium-Competitive Acid Blocker"OR"P-CAB"OR"PCAB"OR"Revaprazan"OR"Linaprazan"OR"Soraprazan"OR"Tegoprazan")].Studies comparing the efficacy of P-CABs-based treatment to classical PPIs in eradicating H.pylori were included.Exclusion criteria included case reports,case series,unpublished trials,or conference abstracts.Data variables encompassed age,diagnosis method,sample sizes,study duration,intervention and control,and H.pylori eradication method were gathered by two independent reviewers.Meta-analysis was performed in R software,and forest plots were generated.RESULTS A total of 256 references were initially retrieved through the search command.Ultimately,fifteen studies(7 RCTs,7 retrospective observational studies,and 1 comparative unique study)were included,comparing P-CAB triple therapy to PPI triple therapy.The intention-to-treat analysis involved 8049 patients,with 4471 in the P-CAB intervention group and 3578 in the PPI control group across these studies.The analysis revealed a significant difference in H.pylori eradication between VPZ triple therapy and PPI triple therapy in both RCTs and observational studies[risk ratio(RR)=1.17,95%confidence interval(CI):1.11-1.22,P<0.0001]and(RR=1.13,95%CI:1.09-1.17,P<0.0001],respectively.However,no significant difference was found between tegoprazan(TPZ)triple therapy and PPI triple therapy in both RCTs and observational studies(RR=1.04,95%CI:0.93-1.16,P=0.5)and(RR=1.03,95%CI:0.97-1.10,P=0.3),respectively.CONCLUSION VPZ-based triple therapy outperformed conventional PPI-based triple therapy in eradicating H.pylori,positioning it as a highly effective first-line regimen.Additionally,TPZ-based triple therapy was non-inferior to classical PPI triple therapy.展开更多
Carbon with its high electrical conductivity,excellent chemical stability,and structure ability is the most promising an-ode material for sodium and potassium ion batteries.We developed a defect-rich porous carbon fra...Carbon with its high electrical conductivity,excellent chemical stability,and structure ability is the most promising an-ode material for sodium and potassium ion batteries.We developed a defect-rich porous carbon framework(DRPCF)built with N/O-co-doped mesoporous nanosheets and containing many defects using porous g-C_(3)N_(4)(PCN)and dopamine(DA)as raw materials.We prepared samples with PCN/DA mass ratios of 1/1,2/1 and 3/1 and found that the one with a mass ratio of 2/1 and a carbonization temperature of 700℃ in an Ar atmosphere(DRPCF-2/1-700),had a large specific surface area with an enormous pore volume and a large number of N/O heteroatom active defect sites.Because of this,it had the best pseudocapacitive sodium and potassium ion stor-age performance.A half battery of Na//DRPCF-2/1-700 maintained a capacity of 328.2 mAh g^(-1) after being cycled at 1 A g^(-1) for 900 cycles,and a half battery of K//DRPC-2/1-700 maintained a capacity of 321.5 mAh g^(-1) after being cycled at 1 A g^(-1) for 1200 cycles.The rate capability and cycling stability achieved by DRPCF-2/1-700 outperforms most reported carbon materials.Finally,ex-situ Raman spectroscopy analysis result confirms that the filling and removing of K^(+)and Na^(+)from the electrochemically active defects are responsible for the high capacity,superior rate and cycling performance of the DRPCF-2/1-700 sample.展开更多
Disturbances of potassium balance are often encountered when managing kidney transplant recipients(KTR).Both hyperkalemia and hypokalemia may present either as medical emergencies or chronic outpatient abnormalities.D...Disturbances of potassium balance are often encountered when managing kidney transplant recipients(KTR).Both hyperkalemia and hypokalemia may present either as medical emergencies or chronic outpatient abnormalities.Despite the high incidence of hyperkalemia and its potential life-threatening implications,consensus on its management in KTR is lacking.Hypokalemia in KTR is also well-described,although it is given less attention by clinicians compared to hyper-kalemia.This article discusses the etiology,pathophysiology and management of both types of potassium disorders in KTR.Once any emergent situation has been corrected,treatment approaches include correcting insulin deficiency if present,adjusting non-immunosuppressive and immunosuppressive medications,elimi-nating or supplementing potassium as needed,and dietary counselling.Although commonly of multifactorial etiology,ascertaining the specific cause in a particular patient will help guide successful management.Monitoring KTR through regular laboratory testing is essential to detect serious disturbances in potassium balance since patients are often asymptomatic.展开更多
Hypokalemia, defined as serum potassium below 3.5 mEq/L, can lead to severe complications such as arrhythmias and muscle paralysis, potentially resulting in rhabdomyolysis. The etiology of hypokalemia is often multifa...Hypokalemia, defined as serum potassium below 3.5 mEq/L, can lead to severe complications such as arrhythmias and muscle paralysis, potentially resulting in rhabdomyolysis. The etiology of hypokalemia is often multifactorial, involving but not limited to gastrointestinal losses, renal losses, medication effects, and inadequate dietary intake. Chronic heavy alcohol use, obstructive sleep apnea (OSA), and the use of diuretics such as hydrochlorothiazide (HCTZ) are also significant contributing factors. Effective management requires thorough evaluation and investigation to effectively treat a patient. This case report aims to illustrate the diagnostic challenges and comprehensive treatment approach required in a patient with multiple comorbidities and severe hypokalemia, emphasizing the need for a multidisciplinary and comprehensive approach to address all underlying causes.展开更多
目的描绘弥漫型胃癌组织中组蛋白H3第27位赖氨酸的三甲基化(H3K27me3)修饰的全基因组分布图谱,通过鉴定H3K27me3所调控的关键靶基因,初步探究H3K27me3修饰重编程可能调控弥漫型胃癌细胞发生发展的作用机制。方法样本来源于2021-2023年...目的描绘弥漫型胃癌组织中组蛋白H3第27位赖氨酸的三甲基化(H3K27me3)修饰的全基因组分布图谱,通过鉴定H3K27me3所调控的关键靶基因,初步探究H3K27me3修饰重编程可能调控弥漫型胃癌细胞发生发展的作用机制。方法样本来源于2021-2023年在陆军特色医学中心消化内科内镜中心及手术室胃肠外科组接受检查或治疗的患者。共收集到正常组患者14例,其中男性6例,女性8例,平均年龄46岁;胃癌组患者14例,其中男性8例,女性6例,平均年龄63岁。采用染色质靶向剪切及转座酶技术(cleavage under target and tagmentation,CUT&Tag)捕获基因组H3K27me3修饰区域,分析H3K27me3修饰重编程特征。整合转录组(RNA‐Seq)测序数据、高通量染色体构象捕获技术(high‐throughput chromosome conformation capture,Hi‐C)及已发表的公共单细胞数据,分析H3K27me3修饰重编程在弥漫型胃癌细胞中所调控靶基因。结果CUT&Tag和RNA测序数据质量符合下游分析标准,正常胃黏膜组织和弥漫型胃癌组织的组蛋白H3K27me3修饰均主要分布于远端基因间区和内含子区。相较于正常组织,胃癌组织的H3K27me3修饰存在显著的重编程特征,表现为H3K27me3总体信号强度明显降低。其中缺失的2912个H3K27me3信号峰可能导致822个肿瘤相关基因的表达上调,这些基因中上调最显著(信号值强度的差异倍数≥2,P<0.05)的56个基因主要富集于哺乳动物雷帕霉素靶蛋白复合体1(mammalian target of rapamycin complex 1,mTORC1)信号通路,其中甲硫氨酸转运体SLC7A5和胱氨酸转运体SLC7A11在胃癌组织中的表达最高。单细胞数据提示,弥漫型胃癌组织中SLC7A11的异常高表达主要存在于肿瘤上皮细胞。利用公共数据和免疫组织化学实验进一步验证SLC7A11在弥漫型胃癌中高表达,且与胃癌患者的不良预后相关。结论组蛋白H3K27me3修饰重编程是弥漫型胃癌的重要表观遗传学特征;组蛋白H3K27me3修饰缺失可能上调肿瘤细胞SLC7A11表达,进而促进肿瘤进展。展开更多
基金funding support from the National Natural Science Foundation of China (52172182, 21975028, 22011540377, 22005035, U21A20172)。
文摘Perovskite solar cell has gained widespread attention as a promising technology for renewable energy.However, their commercial viability has been hampered by their long-term stability and potential Pb leakage. Herein, we demonstrate a bifunctional passivator of the potassium tartrate(PT) to address both challenges. PT minimizes the Pb leakage in perovskites and also heals cationic vacancy defects, resulting in improved device performance and stability. Benefiting from PT modification, the power conversion efficiency(PCE) is improved to 23.26% and the Pb leakage in unencapsulated films is significantly reduced to 9.79 ppm. Furthermore, the corresponding device exhibits no significant decay in PCE after tracking at the maximum power point(MPP) for 2000 h under illumination(LED source, 100 mW cm^(-2)).
文摘BACKGROUND Helicobacter pylori(H.pylori)infects over half the global population,causing gastrointestinal diseases like dyspepsia,gastritis,duodenitis,peptic ulcers,GMALT lymphoma,and gastric adenocarcinoma.Eradicating H.pylori is crucial for treating and preventing these conditions.While conventional proton pump inhibitor(PPI)-based triple therapy is effective,there’s growing interest in longer acid suppression therapies.Potassium competitive acid blocker(P-CAB)triple and dual therapy are new regimens for H.pylori eradication.Initially used in Asian populations,vonoprazan(VPZ)has been recently Food and Drug Administration-approved for H.pylori eradication.AIM To assess the efficacy of regimens containing P-CABs in eradicating H.pylori infection.METHODS This study,following PRISMA 2020 guidelines,conducted a systematic review and meta-analysis by searching MEDLINE and Scopus libraries for randomized clinical trials(RCTs)or observational studies with the following command:[("Helicobacter pylori"OR"H pylori")AND("Treatment"OR"Therapy"OR"Eradication")AND("Vonaprazan"OR"Potassium-Competitive Acid Blocker"OR"P-CAB"OR"PCAB"OR"Revaprazan"OR"Linaprazan"OR"Soraprazan"OR"Tegoprazan")].Studies comparing the efficacy of P-CABs-based treatment to classical PPIs in eradicating H.pylori were included.Exclusion criteria included case reports,case series,unpublished trials,or conference abstracts.Data variables encompassed age,diagnosis method,sample sizes,study duration,intervention and control,and H.pylori eradication method were gathered by two independent reviewers.Meta-analysis was performed in R software,and forest plots were generated.RESULTS A total of 256 references were initially retrieved through the search command.Ultimately,fifteen studies(7 RCTs,7 retrospective observational studies,and 1 comparative unique study)were included,comparing P-CAB triple therapy to PPI triple therapy.The intention-to-treat analysis involved 8049 patients,with 4471 in the P-CAB intervention group and 3578 in the PPI control group across these studies.The analysis revealed a significant difference in H.pylori eradication between VPZ triple therapy and PPI triple therapy in both RCTs and observational studies[risk ratio(RR)=1.17,95%confidence interval(CI):1.11-1.22,P<0.0001]and(RR=1.13,95%CI:1.09-1.17,P<0.0001],respectively.However,no significant difference was found between tegoprazan(TPZ)triple therapy and PPI triple therapy in both RCTs and observational studies(RR=1.04,95%CI:0.93-1.16,P=0.5)and(RR=1.03,95%CI:0.97-1.10,P=0.3),respectively.CONCLUSION VPZ-based triple therapy outperformed conventional PPI-based triple therapy in eradicating H.pylori,positioning it as a highly effective first-line regimen.Additionally,TPZ-based triple therapy was non-inferior to classical PPI triple therapy.
文摘Carbon with its high electrical conductivity,excellent chemical stability,and structure ability is the most promising an-ode material for sodium and potassium ion batteries.We developed a defect-rich porous carbon framework(DRPCF)built with N/O-co-doped mesoporous nanosheets and containing many defects using porous g-C_(3)N_(4)(PCN)and dopamine(DA)as raw materials.We prepared samples with PCN/DA mass ratios of 1/1,2/1 and 3/1 and found that the one with a mass ratio of 2/1 and a carbonization temperature of 700℃ in an Ar atmosphere(DRPCF-2/1-700),had a large specific surface area with an enormous pore volume and a large number of N/O heteroatom active defect sites.Because of this,it had the best pseudocapacitive sodium and potassium ion stor-age performance.A half battery of Na//DRPCF-2/1-700 maintained a capacity of 328.2 mAh g^(-1) after being cycled at 1 A g^(-1) for 900 cycles,and a half battery of K//DRPC-2/1-700 maintained a capacity of 321.5 mAh g^(-1) after being cycled at 1 A g^(-1) for 1200 cycles.The rate capability and cycling stability achieved by DRPCF-2/1-700 outperforms most reported carbon materials.Finally,ex-situ Raman spectroscopy analysis result confirms that the filling and removing of K^(+)and Na^(+)from the electrochemically active defects are responsible for the high capacity,superior rate and cycling performance of the DRPCF-2/1-700 sample.
文摘Disturbances of potassium balance are often encountered when managing kidney transplant recipients(KTR).Both hyperkalemia and hypokalemia may present either as medical emergencies or chronic outpatient abnormalities.Despite the high incidence of hyperkalemia and its potential life-threatening implications,consensus on its management in KTR is lacking.Hypokalemia in KTR is also well-described,although it is given less attention by clinicians compared to hyper-kalemia.This article discusses the etiology,pathophysiology and management of both types of potassium disorders in KTR.Once any emergent situation has been corrected,treatment approaches include correcting insulin deficiency if present,adjusting non-immunosuppressive and immunosuppressive medications,elimi-nating or supplementing potassium as needed,and dietary counselling.Although commonly of multifactorial etiology,ascertaining the specific cause in a particular patient will help guide successful management.Monitoring KTR through regular laboratory testing is essential to detect serious disturbances in potassium balance since patients are often asymptomatic.
文摘Hypokalemia, defined as serum potassium below 3.5 mEq/L, can lead to severe complications such as arrhythmias and muscle paralysis, potentially resulting in rhabdomyolysis. The etiology of hypokalemia is often multifactorial, involving but not limited to gastrointestinal losses, renal losses, medication effects, and inadequate dietary intake. Chronic heavy alcohol use, obstructive sleep apnea (OSA), and the use of diuretics such as hydrochlorothiazide (HCTZ) are also significant contributing factors. Effective management requires thorough evaluation and investigation to effectively treat a patient. This case report aims to illustrate the diagnostic challenges and comprehensive treatment approach required in a patient with multiple comorbidities and severe hypokalemia, emphasizing the need for a multidisciplinary and comprehensive approach to address all underlying causes.
文摘目的描绘弥漫型胃癌组织中组蛋白H3第27位赖氨酸的三甲基化(H3K27me3)修饰的全基因组分布图谱,通过鉴定H3K27me3所调控的关键靶基因,初步探究H3K27me3修饰重编程可能调控弥漫型胃癌细胞发生发展的作用机制。方法样本来源于2021-2023年在陆军特色医学中心消化内科内镜中心及手术室胃肠外科组接受检查或治疗的患者。共收集到正常组患者14例,其中男性6例,女性8例,平均年龄46岁;胃癌组患者14例,其中男性8例,女性6例,平均年龄63岁。采用染色质靶向剪切及转座酶技术(cleavage under target and tagmentation,CUT&Tag)捕获基因组H3K27me3修饰区域,分析H3K27me3修饰重编程特征。整合转录组(RNA‐Seq)测序数据、高通量染色体构象捕获技术(high‐throughput chromosome conformation capture,Hi‐C)及已发表的公共单细胞数据,分析H3K27me3修饰重编程在弥漫型胃癌细胞中所调控靶基因。结果CUT&Tag和RNA测序数据质量符合下游分析标准,正常胃黏膜组织和弥漫型胃癌组织的组蛋白H3K27me3修饰均主要分布于远端基因间区和内含子区。相较于正常组织,胃癌组织的H3K27me3修饰存在显著的重编程特征,表现为H3K27me3总体信号强度明显降低。其中缺失的2912个H3K27me3信号峰可能导致822个肿瘤相关基因的表达上调,这些基因中上调最显著(信号值强度的差异倍数≥2,P<0.05)的56个基因主要富集于哺乳动物雷帕霉素靶蛋白复合体1(mammalian target of rapamycin complex 1,mTORC1)信号通路,其中甲硫氨酸转运体SLC7A5和胱氨酸转运体SLC7A11在胃癌组织中的表达最高。单细胞数据提示,弥漫型胃癌组织中SLC7A11的异常高表达主要存在于肿瘤上皮细胞。利用公共数据和免疫组织化学实验进一步验证SLC7A11在弥漫型胃癌中高表达,且与胃癌患者的不良预后相关。结论组蛋白H3K27me3修饰重编程是弥漫型胃癌的重要表观遗传学特征;组蛋白H3K27me3修饰缺失可能上调肿瘤细胞SLC7A11表达,进而促进肿瘤进展。
